Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-04
2007-12-04
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S224000, C544S242000, C544S333000, C548S302700, C514S387000
Reexamination Certificate
active
11034701
ABSTRACT:
Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
REFERENCES:
patent: 6355664 (2002-03-01), Kelly et al.
patent: 6437148 (2002-08-01), Frutos et al.
patent: 6492408 (2002-12-01), Wu et al.
patent: 6689804 (2004-02-01), Wu et al.
patent: 6844360 (2005-01-01), Kelly et al.
patent: 6852748 (2005-02-01), Kelly et al.
patent: WO 98/39303 (1998-09-01), None
patent: WO 01/07440 (2001-02-01), None
Springer, T. A.; “Adhesion receptors of the immune system”; Nature, 1990, 346, pp. 425-434.
Kishimoto, T. K. et al: “Integrins, ICAMs, and Selectins: Role and Regulation of Adhesion Molecules in Neutrophil Recruitment to Inflammatory Sites”; Adv. Pharmacol. 1994, 25, pp. 117-138.
Diamond, M. S.; “The dynamic regulation of integrin adhesiveness”; Current Biology, 1994, 4, pp. 506-517.
Anderson, D. C. et al; “Leukocyte LFA-1, OKM1, p150,95 deficiency syndrome: functional and biosynthetic studies of three kindreds 1,2”; Fed. Proc. 1985, 44, pp. 2671-2677.
Anderson, D. C. et al; “The Severe and Moderate Phenotypes of Heritable Mac-1,LFA-1 Deficiency: Their Quantitative Definition and Relation to Leukocyte Dysfunction and Clinical Features”: J. Infect. Dis., 1985, 152, pp. 668-689.
Gorski, A.; “The role of cell adhesion molecules in immunopathology”; Immunology Today, 1994, 15, pp. 251-255.
Rothlein, R. et al; “1. Leukocyte Adhesion in Inflammation: From Discovery to the Clinic”: Adhesion, Molecules; Wegner, C. D., ed.; 1994, pp. 1-8.
Cosimi, A. B. et al; “In Vivo Effects Of Monoclonal Antibody To ICAM-1 (CD54) In Nonhuman Primates With Renal Allografts1”; J. Immunol. 1990, 144, pp. 4604-4612.
Kavanaugh, A. F. et al; “Treatment of Refractory Rheumatoid Arthritis With A Monoclonal Antibody To Intercellular Adhesion Molecule 1”; Arthritis Rheum. 1994, 37, pp. 992-1004.
Fischer, A. et al; “Prevention of Graft Failure By An Anti-HLFA-1 Monoclonal Antibody in HLA-Mismatched Bone-Marrow Transplantation”; Lancet, 1989, 2 pgs 1058-1060.
LeMauff, B. et al; “Effect of Anti-LFA1 (CD11a) Monoclonal Antibodies in Acute Rejection In Human Kidney Transplantation”; Transplantation, 1991, 52, pp. 291-295.
Becker, J. C. et al; “Soluble Intercellular Adhesion Molecule-1 Inhibits MHC-Restricted Specific T Cell/Tumor Interation”; J. Immuno., 1993, 151, pp. 7224-7232.
Roep, B. O., et al; “Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus”; Lancet, 1994, 343, pp. 1590-1593.
Kelly Terence Alfred
Kim Jin Mi
Lemieux René Marc
Boehringer Ingelheim Pharmaceuticals Inc.
Datlow Philip I.
Devlin Mary-Ellen M.
Morris Michael P.
Shameem Golam M. M.
LandOfFree
Derivatives of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3893387